Role of Neoadjuvant Paclitaxel Chemotherapy in Carcinoma Breast: A Prospective Study

Abstract

Objective: The purpose of this prospective study was to assess the value of neoadjuvant chemotherapy with paclitaxel in the treatment of breast cancer. Methods: There were 88 diagnosed breast cancer patients altogether, 44 in each of the two groups (paclitaxel group and control group). To verify eligibility, thorough clinical, radiological, and laboratory evaluations were made. The reduction of tumor size, pathological reactions, and safety profiles were evaluated. To compare results between groups, statistical tests were used during data processing. Results: At 12 and 24 weeks, the paclitaxel group showed significantly smaller tumor sizes than the control group. In the paclitaxel group, complete pathological responses were more common, indicating efficient tumor regression. The side effects of paclitaxel therapy were generally well-tolerated and controllable. Conclusion: In conclusion, patients with breast cancer showed encouraging improvements in histological responses and tumor size after neoadjuvant paclitaxel treatment. These results suggest the potential advantages of using paclitaxel in neoadjuvant therapy protocols, perhaps making breast-conserving surgery more feasible. In order to provide more individualized treatments, future research should investigate long-term outcomes and biomarkers indicative of paclitaxel sensitivity